John Levine
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, John Levine sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
John Levine: 5 sponsored US clinical trials, 1 recruiting.
John Levine sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Adverse Effects, with 2 trials.
Upper-quartile sponsor footprint
John Levine sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
MAGIC Ruxolitinib for aGVHD
NCT06936566
Pediatric GVHD Low Risk Steroid Taper Trial
NCT05090384
Itacitinib for Low Risk GVHD
NCT03846479
A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD
NCT03459040
Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
NCT02133924
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 5 |
Therapeutic Areas
What is open in the John Levine pipeline
1 recruiting of 5 indexed (20% open); 3 completed (60%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Adverse Effects (2 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
John Levine: open-pipeline peers nationwide
Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
John Levine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
- Amazentis · 20% recruiting · 5 trials
Related
What to do with this John Levine page
5 registered trials is a research-attention snapshot, not an endorsement of John Levine or any single study.
- 1 of John Levine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Adverse Effects is the condition John Levine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Adverse Effects trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. John Levine pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.